Since rapamycin (ABI-009) inhibits the mTOR pathway, resulting in the downregulation of manganese superoxide dismutase (MnSOD) expression, it has been revealed that rapamycin (ABI-009) reduces the number of mammospheres, which are the markers of breast cancer development, and makes breast CSCs sensitive to radiation therapy [159]. Here, MTOR is linked to breast carcinoma.